|
|
||||||||





*
Division of Nephrology, Childrens Hospital, Harvard Medical School, Boston, MA 02115;
Laboratory of Immunogenetics and Transplantation, Department of Medicine, Brigham and Womens Hospital, Harvard Medical School, Boston, MA 02115; and
Center for Neurologic Diseases, Brigham and Womens Hospital, Harvard Medical School, Boston, MA 02115
MDR1 P-glycoprotein (P-gp), the multidrug resistance-associated
transmembrane transporter, is physiologically expressed by human
peripheral immune cells, but its role in cell-mediated immunity remains
poorly understood. Here, we demonstrate a novel role for P-gp in
alloantigen-dependent human T cell activation. The pharmacologic P-gp
inhibitor tamoxifen (110 µM) and the MDR1 P-gp-specific mAb Hyb-241
(120 µg/ml), which detected surface P-gp on 21% of human
CD3+ T cells and 84% of CD14+ APCs in our
studies, inhibited alloantigen-dependent, but not mitogen-dependent, T
cell proliferation in a dose-dependent manner from 4090%
(p < 0.01). The specific inhibitory effect on
alloimmune T cell activation was associated with >85% inhibition
(p < 0.01) of IL-2, IFN-
, and TNF-
production in 48-h MLR coculture supernatants. Addition of recombinant
human IL-2 (0.110 ng/ml) restored proliferation in tamoxifen-treated
cocultures. Pretreatment of purified CD4+ T cells with
Hyb-241 mAb before coculture resulted in inhibition of CD4+
T cellular IFN-
secretion. Also, blockade of P-gp on allogeneic APCs
inhibited IL-12 secretion. Taken together these results demonstrate
that P-gp is functional on both CD4+ T cells and
CD14+ APCs, and that P-gp blockade may attenuate both
IFN-
and IL-12 through a positive feedback loop. Our results define
a novel role for P-gp in alloimmunity and thus raise the intriguing
possibility that P-gp may represent a novel therapeutic target in
allograft rejection.
This article has been cited by other articles:
![]() |
R. van de Ven, R. Oerlemans, J. W. van der Heijden, G. L. Scheffer, T. D. de Gruijl, G. Jansen, and R. J. Scheper ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer J. Leukoc. Biol., November 1, 2009; 86(5): 1075 - 1087. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Y. Frank, A. T. Kho, T. Schatton, G. F. Murphy, M. J. Molloy, Q. Zhan, M. F. Ramoni, M. H. Frank, I. S. Kohane, and E. Gussoni Regulation of myogenic progenitor proliferation in human fetal skeletal muscle by BMP4 and its antagonist Gremlin J. Cell Biol., October 9, 2006; 175(1): 99 - 110. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Y. Frank, A. Margaryan, Y. Huang, T. Schatton, A. M. Waaga-Gasser, M. Gasser, M. H. Sayegh, W. Sadee, and M. H. Frank ABCB5-Mediated Doxorubicin Transport and Chemoresistance in Human Malignant Melanoma Cancer Res., May 15, 2005; 65(10): 4320 - 4333. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Y. Frank, S. S. Pendse, P. H. Lapchak, A. Margaryan, D. Shlain, C. Doeing, M. H. Sayegh, and M. H. Frank Regulation of Progenitor Cell Fusion by ABCB5 P-glycoprotein, a Novel Human ATP-binding Cassette Transporter J. Biol. Chem., November 21, 2003; 278(47): 47156 - 47165. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Anglicheau, C. Verstuyft, P. Laurent-Puig, L. Becquemont, M.-H. Schlageter, B. Cassinat, P. Beaune, C. Legendre, and E. Thervet Association of the Multidrug Resistance-1 Gene Single-Nucleotide Polymorphisms with the Tacrolimus Dose Requirements in Renal Transplant Recipients J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1889 - 1896. [Abstract] [Full Text] [PDF] |
||||
![]() |
E.-F. Solomayer, M. Feuerer, L. Bai, V. Umansky, P. Beckhove, G. C. Meyberg, G. Bastert, V. Schirrmacher, and I. J. Diel Influence of Adjuvant Hormone Therapy and Chemotherapy on the Immune System Analysed in the Bone Marrow of Patients with Breast Cancer Clin. Cancer Res., January 1, 2003; 9(1): 174 - 180. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chiampanichayakul, A. Szekeres, P. Khunkaewla, S. Moonsom, V. Leksa, K. Drbal, G. J. Zlabinger, R. Hofer-Warbinek, H. Stockinger, and W. Kasinrerk Engagement of Na,K-ATPase {beta}3 subunit by a specific mAb suppresses T and B lymphocyte activation Int. Immunol., December 1, 2002; 14(12): 1407 - 1414. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |